Fadi Chaaban, MD
Cardiovascular Disease · West Orange, NJNPI 1316947906
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,683 of the $160,943 with a category attached, or 86.2%. 47 manufacturers reported payments, led by Johnson & Johnson at 43.2% of the total. Reporting peaked in 2019 at $44,961 and has fallen 69.7% since, to $13,632 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 695 payments — averaging $231.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$69K
- Boehringer Ingelheim$68K
- Lilly USA, LLC$10K
- Novo Nordisk$5K
- Amgen$1K
- Novartis$1K
- plus $6K from 41 others
What the payments were for
- Consulting fees$5,1003%
- Speaking & faculty fees$138,68386%
- Travel & lodging$3,0622%
- Food & beverage$14,0579%
- Education$300%
- Other$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$76,638
- XARELTO$68,362
- Repatha$473
- ANDEXXA$256
- VERQUVO$250
- Veltassa$200
- WATCHMAN FLX$148
- KONECT RESILIA$130
- GENERAL - THERAPIES$125
- Reveal LINQ$125
- ELIQUIS$119
- SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH THE SHOCKWAVE C2+ CORONARY$100
How this compares
$160,943 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 485 | $494,719 |
| XareltoRivaroxaban | 321 | $342,731 |
| EntrestoSacubitril/Valsartan | 288 | $287,139 |
| JardianceEmpagliflozin | 149 | $150,832 |
| MultaqDronedarone Hcl | 70 | $88,972 |
| BrilintaTicagrelor | 50 | $41,502 |
| Repatha SureclickEvolocumab | 61 | $39,843 |
| VerquvoVericiguat | 16 | $23,989 |
| Ezetimibe | 835 | $20,269 |
| VascepaIcosapent Ethyl | 27 | $18,259 |
| Metoprolol Succinate | 1,286 | $17,501 |
| Atorvastatin Calcium | 1,286 | $14,104 |
| Rosuvastatin Calcium | 681 | $11,186 |
| Icosapent Ethyl | 17 | $9,927 |
| Carvedilol ErCarvedilol Phosphate | 16 | $9,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $749 | $494,719485 claims |
| Johnson & JohnsonXarelto | $69,480 | $342,731321 claims |
| NovartisEntresto | $1,066 | $287,139288 claims |
| Boehringer IngelheimJardiance | $68,034 | $150,832149 claims |
| Sanofi-aventis U.S. LLCMultaq | $104 | $88,97270 claims |
| AstraZenecaBrilinta | $593 | $41,50250 claims |
| MerckVerquvo | $756 | $23,98916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in West Orange
- Sabino TorreWest Orange$57K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.